Please login to the form below

Not currently logged in
Email:
Password:

EU clears Gilead's hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus
Gilead Sciences

Gilead Sciences has been granted approval by the European Commission (EC) for Sovaldi, getting a green light for the first all-oral treatment for chronic hepatitis C virus in the EU.

The European regulator approved Sovaldi (sofosbuvir) for use both in combination with pegylated interferon alpha and ribavirin in patients with hepatitis C genotypes 1, 4, 5 or 6, and as an interferon-free regimen alongside ribavirin alone in patients with hepatitis C genotypes 2 or 3 or those awaiting a liver transplant.

Gilead's drug - which is the first compound in the NS5B polymerase inhibitor class to be registered - was approved for the same indication in the US in December 2013, and analysts are already predicting that it could reach blockbuster sales levels of $1bn or more by the end of this year and $5bn or more at peak.

One reason for the anticipated rapid take-up of Sovaldi is that hepatitis C patients have been delaying treatment - a phenomenon known as 'warehousing' - in anticipation of the availability of more effective and tolerable new therapies.

Commenting on the EU approval of Gilead's drug, hepatologist Graham Foster of Queen Mary University in London, UK, said: "With high cure rates across a broad range of patients and a short duration of therapy, Sovaldi is a very welcome therapeutic advance."

Despite the fact that hepatitis C is curable, there is a pressing need for new and improved therapies because "many hepatitis C virus patients have not currently achieved a cure and often progress to end-stage liver disease or liver cancer," he added.

Gilead notes that approximately nine million people in Europe are infected with hepatitis C virus, which is a major cause of liver cancer and liver transplantation.

EU approval of Sovaldi is also a boost for Bristol-Myers Squibb (BMS), which moved a step closer to approval of a combination regimen of sofosbuvir and its NS5A inhibitor daclatasvir earlier this year after the EMA's Committee for Medicinal Products for Human use said the two drugs could be used on a compassionate basis in hepatitis C patients at high risk of liver failure or death.

BMS is hoping to position daclatasvir alongside sofosbuvir as the basis of an all-oral, interferon-free regimen of choice for hepatitis C.

Meanwhile, a host of other drugmakers are also vying for a share of the interferon-free market for hepatitis C, including Johnson & Johnson and Medivir, whose protease inhibitor Olysio (simeprevir) was cleared in the US in November 2013. The likes of AbbVie, Boehringer Ingelheim and Merck & Co all also have candidates in development.

Article by
Phil Taylor

20th January 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...